Coagulation Factor Viia Dosage
Medically reviewed by Drugs.com. Last updated on Oct 8, 2024.
Applies to the following strengths: 1000 mcg (1 mg); 2000 mcg (2 mg); 8000 mcg (8 mg); 5000 mcg (5 mg); 1200 mcg (1.2 mg); 2400 mcg (2.4 mg); 4800 mcg (4.8 mg); jncw 1000 mcg (1 mg); jncw 2000 mcg (2 mg); jncw 5000 mcg (5 mg)
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Hemophilia A
CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS:
Hemostatic:
90 mcg/kg IV bolus injection once every 2 hours (adjustable based on bleeding severity) until hemostasis is achieved or treatment is deemed inadequate
Post-hemostatic:
90 mcg/kg IV bolus injection once every 3 to 6 hours for severe bleeds
Perioperative Management:
Initial: 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 hours for surgery duration (additional bolus doses may be required with major surgery).
Post-surgical:
- Minor surgery: 90 mcg/kg IV bolus injection once every 2 hours for 48 hours, then every 2 to 6 hours until healing occurs.
- Major surgery: 90 mcg/kg IV bolus injection once every 2 hours for 5 days, then every 4 hours until healing occurs.
ACQUIRED HEMOPHILIA:
Non-perioperative Management:
70 to 90 mcg/kg IV bolus injection once every 2 to 3 hours until hemostasis is achieved
Perioperative Management:
70 to 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 to 3 hours for surgery duration and until hemostasis is achieved.
Usual Adult Dose for Hemophilia B
CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS:
Hemostatic:
90 mcg/kg IV bolus injection once every 2 hours (adjustable based on bleeding severity) until hemostasis is achieved or treatment is deemed inadequate
Post-hemostatic:
90 mcg/kg IV bolus injection once every 3 to 6 hours for severe bleeds
Perioperative Management:
Initial: 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 hours for surgery duration (additional bolus doses may be required with major surgery).
Post-surgical:
- Minor surgery: 90 mcg/kg IV bolus injection once every 2 hours for 48 hours, then every 2 to 6 hours until healing occurs.
- Major surgery: 90 mcg/kg IV bolus injection once every 2 hours for 5 days, then every 4 hours until healing occurs.
ACQUIRED HEMOPHILIA:
Non-perioperative Management:
70 to 90 mcg/kg IV bolus injection once every 2 to 3 hours until hemostasis is achieved
Perioperative Management:
70 to 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 to 3 hours for surgery duration and until hemostasis is achieved.
Usual Adult Dose for Factor VII Deficiency
15 to 30 mcg/kg IV bolus injection once every 4 to 6 hours until hemostasis is achieved
Comments: Doses as low as 10 mcg/kg have been effective.
Usual Adult Dose for Glanzmann's Thrombasthenia
Non-perioperative Management:
90 mcg/kg IV bolus injection once every 2 to 6 hours until hemostasis is achieved in severe bleeding episodes requiring systemic hemostatic therapy
Perioperative Management:
Initial: 90 mcg/kg IV bolus injection immediately before surgery; repeat every 2 hours for procedure duration.
Post-surgical: 90 mcg/kg IV bolus injection once every 2 to 6 hours
Usual Pediatric Dose for Hemophilia A
CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS:
Hemostatic:
90 mcg/kg IV bolus injection once every 2 hours (adjustable based on bleeding severity) until hemostasis is achieved or treatment is deemed inadequate
Post-hemostatic:
90 mcg/kg IV bolus injection once every 3 to 6 hours for severe bleeds
Perioperative Management:
Initial: 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 hours for surgery duration (additional bolus doses may be required with major surgery).
Post-surgical:
- Minor surgery: 90 mcg/kg IV bolus injection once every 2 hours for 48 hours, then every 2 to 6 hours until healing occurs.
- Major surgery: 90 mcg/kg IV bolus injection once every 2 hours for 5 days, then every 4 hours until healing occurs.
ACQUIRED HEMOPHILIA:
Non-perioperative Management:
70 to 90 mcg/kg IV bolus injection once every 2 to 3 hours until hemostasis is achieved
Perioperative Management:
70 to 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 to 3 hours for surgery duration and until hemostasis is achieved.
Usual Pediatric Dose for Hemophilia B
CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS:
Hemostatic:
90 mcg/kg IV bolus injection once every 2 hours (adjustable based on bleeding severity) until hemostasis is achieved or treatment is deemed inadequate
Post-hemostatic:
90 mcg/kg IV bolus injection once every 3 to 6 hours for severe bleeds
Perioperative Management:
Initial: 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 hours for surgery duration (additional bolus doses may be required with major surgery).
Post-surgical:
- Minor surgery: 90 mcg/kg IV bolus injection once every 2 hours for 48 hours, then every 2 to 6 hours until healing occurs.
- Major surgery: 90 mcg/kg IV bolus injection once every 2 hours for 5 days, then every 4 hours until healing occurs.
ACQUIRED HEMOPHILIA:
Non-perioperative Management:
70 to 90 mcg/kg IV bolus injection once every 2 to 3 hours until hemostasis is achieved
Perioperative Management:
70 to 90 mcg/kg IV bolus injection once immediately before surgery; repeat every 2 to 3 hours for surgery duration and until hemostasis is achieved.
Usual Pediatric Dose for Factor VII Deficiency
15 to 30 mcg/kg IV bolus injection once every 4 to 6 hours until hemostasis is achieved
Comments: Doses as low as 10 mcg/kg have been effective.
Usual Pediatric Dose for Glanzmann's Thrombasthenia
Non-perioperative Management:
90 mcg/kg IV bolus injection once every 2 to 6 hours until hemostasis is achieved in severe bleeding episodes requiring systemic hemostatic therapy
Perioperative Management:
Initial: 90 mcg/kg IV bolus injection immediately before surgery; repeat every 2 hours for procedure duration.
Post-surgical: 90 mcg/kg IV bolus injection once every 2 to 6 hours
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
US BOXED WARNING:
- THROMBOSIS: Serious arterial and venous thrombotic events have been reported following administration of this drug. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive this drug. Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.
Safety and efficacy have not been established to determine differences among age groups (0 to 16 years); clinical trials were conducted with dosing based on body weight, not age.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For IV bolus injection only.
- Administer as soon as possible following bleeding onset or immediately before scheduled procedure.
- The manufacturer product information should be consulted.
Storage requirements:
- Prior to reconstitution: Store powder and histidine diluent between 2 and 25C (36 to 77F); do not freeze; protect from light.
- After reconstitution: Store at room temperature or refrigerated up to 3 hours; do not freeze or store in syringes.
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
IV compatibility: Do not mix with other infusion solutions.
General:
- Coagulation parameters do not necessarily correlate with or predict effectiveness of this drug; use hemostasis evaluation to determine effectiveness.
- Congenital hemophilia A or B with inhibitors: Outcome decision was made for a majority of patients treated for joint or muscle bleeds within 8 doses; more doses were required for severe bleeds. A majority of patients who reported adverse experiences received more than 12 doses.
Monitoring:
- Monitor for signs or symptoms of activation of the coagulation system or thrombosis.
- Monitor and minimize the duration of any post-hemostatic dosing.
- Monitor prothrombin time (PT) and factor VII coagulant activity in factor VII deficient patients before and after administering this drug.
- Monitor for factor VII antibodies in factor VII deficient patients treated with this drug.
Patient advice:
- Inform patients to seek immediate medical attention if early signs of hypersensitivity occur (e.g., hives, urticaria, chest tightness, wheezing, hypotension, and anaphylaxis).
- Advise patients to seek immediate medical attention if signs of thrombosis occur (e.g., new onset swelling and pain in the limbs or abdomen, new onset chest pain, shortness of breath, loss of sensation or motor power, or altered consciousness or speech).
More about coagulation factor viia
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: miscellaneous coagulation modifiers
- En español
Patient resources
- Coagulation factor VIIa injection drug information
- Coagulation factor viia (Advanced Reading)
- Coagulation factor viia-jncw (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
